| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NCT05131022) | Nurix Therapeutics, Inc. | 2022-04-13 |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma (NCT05144347) | Exelixis | 2022-04-12 |
| Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (NCT05098613) | University of Colorado, Denver | 2021-12-21 |
| DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489) | Miltenyi Biomedicine GmbH | 2021-05-25 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04830137) | Nurix Therapeutics, Inc. | 2021-05-05 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (NCT04767308) | Huazhong University of Science and Technology | 2021-03-01 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years (NCT05406154) | Peking University Third Hospital | 2020-12-30 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520) | Medical College of Wisconsin | 2020-05-18 |
| ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (NCT04049513) | Malaghan Institute of Medical Research | 2019-10-11 |
| A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma (NCT03877055) | Memorial Sloan Kettering Cancer Center | 2019-03-13 |
| REal World Data in LYmphoma and Survival in Adults (NCT03869619) | Hospices Civils de Lyon | 2018-11-14 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (NCT03571828) | Amgen | 2018-10-29 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
| Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 (NCT03265158) | Royal Marsden NHS Foundation Trust | 2017-07-19 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma (NCT02914938) | MEI Pharma, Inc. | 2016-10-01 |
| A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL (NCT02717624) | Acerta Pharma BV | 2016-04-20 |
| An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma (NCT02213926) | Acerta Pharma BV | 2015-03-02 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |